Related Experiment Video
Updated: Sep 27, 2025
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
Published on: August 18, 2023
CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer
Aimin Jiang1, Ye Zhou1, Wenliang Gong1
1Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Background:
Cancer is a major threat to human health worldwide. Although recent innovations and advances in early detection and effective therapies such as targeted drugs and immune checkpoint inhibitors have saved more lives of cancer patients and improved their quality of life, our knowledge about cancer remains largely unknown. CCNA2 belongs to the cell cyclin family and has been demonstrated to be a tumorigenic gene in multiple solid tumor types. The aim of the present study was to make a comprehensive analysis on the role of CCNA2 at a pancancer level.
Methods:
Multidatabases were collected to evaluate the different expression, prognostic value, DNA methylation, tumor mutation burden, microsatellite instability, mismatch repair, tumor immune microenvironment, and drug sensitivity of CCNA2 across pancancer. IHC was utilized to validate the expression and prognostic value of CCNA2 in ccRCC patients from SMMU cohort.
Results:
CCNA2 was differentially expressed in most cancer types vs. normal tissues. CCNA2 may significantly influence the prognosis of multiple cancer types, especially clear cell renal cell carcinoma (ccRCC). CCNA2 was also frequently mutated in most cancer types. Notably, CCNA2 was significantly correlated with immune cell infiltration and immune checkpoint inhibitory genes. In addition, CCNA2 was also strongly related to drug resistance.
Conclusion:
CCNA2 may prove to be a new biomarker for prognostic prediction, tumor immunity assessment, and drug susceptibility evaluation in pancancer level, especially in ccRCC.
Insights
Cyclin A2 (CCNA2) is frequently altered in many cancers and impacts patient prognosis. This study reveals CCNA2 as a potential biomarker for predicting cancer outcomes, immune response, and drug sensitivity across various cancer types.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer remains a significant global health challenge despite therapeutic advances.
- Cyclin A2 (CCNA2), a cell cyclin family member, is implicated as a tumorigenic gene in various solid tumors.
- Comprehensive understanding of CCNA2's role across diverse cancer types is limited.
Purpose of the Study:
- To conduct a comprehensive pancan (pancancer) analysis of CCNA2's function.
- To evaluate CCNA2's differential expression, prognostic significance, and molecular characteristics across multiple cancer types.
Main Methods:
- Utilized multidatabase analysis to assess CCNA2 expression, prognosis, DNA methylation, mutation burden, and immune microenvironment.
- Investigated CCNA2's correlation with microsatellite instability, mismatch repair, and drug sensitivity.
- Employed immunohistochemistry (IHC) for validating CCNA2 expression and prognostic value in clear cell renal cell carcinoma (ccRCC).
Main Results:
- CCNA2 exhibited differential expression in most cancer types compared to normal tissues.
- CCNA2 significantly correlated with prognosis in multiple cancers, particularly ccRCC.
- CCNA2 alterations were frequent, and the gene showed strong associations with immune cell infiltration, immune checkpoint genes, and drug resistance.
Conclusions:
- CCNA2 demonstrates potential as a novel biomarker for prognostic prediction in pancancer.
- CCNA2 may serve as a valuable indicator for assessing tumor immunity and drug susceptibility.
- The findings highlight CCNA2's specific importance in clear cell renal cell carcinoma (ccRCC).
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment
02:39lncRNA - Long Non-coding RNAs